[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK: Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg; 2003 Nov;126(5):1603-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
  • OBJECTIVE: Paclitaxel has one of the highest response rates when used as a single agent in patients with esophageal cancer.
  • The combination of paclitaxel and carboplatin has been shown to be a well-tolerated and safe regimen in non-small cell lung cancer.
  • The objective of this study was to determine the efficacy of preoperative paclitaxel and carboplatin in patients with carcinoma of the esophagus.
  • Patients with stage I disease and those with visceral metastases were excluded.
  • All underwent preoperative computed tomography scanning and endosonography for staging.
  • Preoperative staging showed: stage IIA, 6 patients; stage IIB, 1 patient; and stage III, 19 patients.
  • All patients completed their preoperative chemotherapy.
  • There was no unexpected chemotherapy-related toxicity.
  • A complete pathologic response was seen in 11% of all patients and in 25% of those with epidermoid cancer.
  • CONCLUSION: Paclitaxel-carboplatin combination is a safe and well-tolerated regimen for esophageal cancer with clinical response rates comparable to historical controls.
  • This regimen may be especially suitable for patients with epidermoid cancer, who had a 25% pathological complete response in this report.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / mortality. Paclitaxel / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Analysis of Variance. Biopsy, Needle. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Esophagectomy / methods. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Pilot Projects. Preoperative Care / methods. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666040.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Machlenkin S, Melzer E, Idelevich E, Ziv-Sokolovsky N, Klein Y, Kashtan H: Endoscopic ultrasound: doubtful accuracy for restaging esophageal cancer after preoperative chemotherapy. Isr Med Assoc J; 2009 Mar;11(3):166-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound: doubtful accuracy for restaging esophageal cancer after preoperative chemotherapy.
  • BACKGROUND: The role of endoscopic ultrasound in evaluating the response of esophageal cancer to neoadjuvant chemotherapy is controversial.
  • METHODS: The disease stage of patients with esophageal cancer was established by means of the TNM classification system.
  • The initial staging was determined by chest and abdominal computed tomography and EUS.
  • Upon completion of the chemotherapy, patients were restaged and then underwent esophagectomy.
  • RESULTS: NAC was conducted in 20 patients with initial stage IIB and III carcinoma of the esophagus (study group).
  • Post-chemotherapy EUS accurately predicted the surgical pathology stage in 6 patients (30%).
  • The accuracy of EUS in determining the T status alone was 80%.
  • Thirteen patients with initial stage I-IIA underwent primary esophagectomy after the initial staging (control group).
  • EUS accurately predicted the surgical pathology disease stage in 11 patients (85%).
  • CONCLUSIONS: EUS is an accurate modality for initial staging of esophageal carcinoma.
  • However, it is not a reliable tool for restaging esophageal cancer after NAC and it cannot predict response to chemotherapy.
  • [MeSH-major] Endosonography. Esophageal Neoplasms / pathology. Esophageal Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Esophagectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging / methods. Postoperative Period. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544707.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


3. Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, Altorki NK: Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg; 2010 Feb;139(2):387-94
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer.
  • OBJECTIVE: In patients with esophageal cancer, a complete pathologic response after preoperative therapy is universally regarded as a favorable prognostic factor.
  • METHODS: We reviewed a prospectively maintained esophageal cancer database.
  • Patients with positive lymph nodes after preoperative therapy and surgery were selected.
  • RESULTS: Ninety-six patients with 1 or more positive nodes received preoperative therapy.
  • Final pathologic stages were IIB in 18 (19%), III in 49 (51%), and IV in 29 (30%).
  • Postoperatively, 44 (46%) patients received additional chemotherapy.
  • On univariate analysis, pathologic stage, pathologic T classification, and number of positive nodes significantly affected overall survival.
  • On multivariate analysis, clinical stage (hazard ratio [HR], 2.25; P = .05), pathologic T classification (HR, 3.06; P = .006), and number of positive nodes (HR 1.03 per node, P = .09) were significant predictors of overall survival.
  • CONCLUSION: Long-term survival can be achieved in patients with esophageal cancer who have persistent nodal disease after neoadjuvant therapy and surgical resection.
  • Clinical stage, pathologic T classification, and number of positive nodes best predict survival.
  • Postoperative chemotherapy conferred no additional survival benefit in this patient population.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Esophagectomy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Patient Selection. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Mosby, Inc.
  • (PMID = 20006355.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1-RR024996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV: NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg; 2004 Apr;239(4):491-500
Hazardous Substances Data Bank. DEOXYCHOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
  • OBJECTIVE: To examine the expression of the transcription factor nuclear factor kappa B (NF-kappaB) in Barrett's epithelium and adenocarcinoma and the impact of NF-kappaB expression on tumor stage and response to neoadjuvant chemotherapy and radiation therapy.
  • SUMMARY BACKGROUND DATA: Progression of Barrett's esophagus to adenocarcinoma is associated with a wide range of cellular and molecular abnormalities.
  • Nuclear factor-kappa B (NF-kappaB) regulates several genes involved in inflammatory, immune and apoptotic responses, but its role in esophageal inflammation and tumorigenesis has not been reported.
  • METHODS: Mobility shift assay was used to measure NF-kappaB activity in nuclear extracts of fresh-frozen biopsies from tumor and uninvolved tissues (n = 30) and esophageal cell lines OE33, SKGT-4, and OE21.
  • RESULTS: NF-kappaB was not expressed in normal esophageal squamous epithelium, in contrast to increased expression in 40% of patients with Barrett's epithelium.
  • Sixty-one percent of resected tumors (n = 97) displayed NF-kappaB immunoreactivity, and 87.5% of the NF-kappaB-positive tumors were Stage IIb and III compared with only 12.5% of patients with Stage I and IIa disease (P < 0.05).
  • The expression of NF-kappaB inversely correlated with major or complete pathologic responses to neoadjuvant chemotherapy and radiation therapy, with 15/20 (75%) responders in the NF-kappaB-negative group compared with 7/38 (18%) in the NF-kappaB-positive group (P < 0.00001).
  • Moreover, incubation of esophageal cell lines OE33, SKGT-4, and OE21 with deoxycholic acid or low pH induced NF-kappaB expression.
  • CONCLUSIONS: Bile acids and low pH induce NF-kappaB expression in esophageal cell lines.
  • NF-kappaB activation is common in esophageal adenocarcinoma.
  • In patients with Barrett's epithelium and an associated esophageal adenocarcinoma, there is a progressive expression of NF-kappaB through Barrett's tumorigenesis.
  • The absence of NF-kappaB expression in esophageal adenocarcinoma correlates with response to neoadjuvant chemoradiotherapy and may be of value in predicting response to neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / therapy. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / therapy. NF-kappa B / genetics
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bile Acids and Salts / pharmacology. Cell Line, Tumor. Cell Transformation, Neoplastic. Chemotherapy, Adjuvant / methods. Deoxycholic Acid / pharmacology. Esophagectomy / methods. Humans. Hydrogen-Ion Concentration. Neoadjuvant Therapy / methods. Neoplasm Staging. Predictive Value of Tests. Radiotherapy, Adjuvant / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Annu Rev Immunol. 1994;12:141-79 [8011280.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Science. 1996 Nov 1;274(5288):784-7 [8864119.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Med. 1999 Apr;5(4):412-7 [10202930.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2567-77 [10353600.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):717-25 [10370600.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 29;1424(1):R37-42 [10456034.001]
  • [Cites] Cell. 1996 Nov 1;87(3):565-76 [8898208.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] N Engl J Med. 1997 Apr 10;336(15):1066-71 [9091804.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] Dis Esophagus. 1999;12(3):177-80 [10631908.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):303-21 [10714623.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1085-9 [11007945.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2274-81 [11147598.001]
  • [Cites] J Clin Invest. 2001 Jan;107(2):135-42 [11160126.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):338-56 [11260097.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:359-69 [11506828.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Res. 1981 Sep;41(9 Pt 2):3759-60 [7260943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40 [2494664.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Gut. 1992 Nov;33(11):1454-8 [1452066.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] J Immunol Methods. 1993 Feb 3;158(2):207-14 [8429227.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • (PMID = 15024310.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bile Acids and Salts; 0 / NF-kappa B; 005990WHZZ / Deoxycholic Acid
  • [Other-IDs] NLM/ PMC1356254
  •  go-up   go-down


5. Mariette C, Piessen G, Triboulet JP: [Is there still a role for surgery in esophageal carcinoma in 2007?]. Bull Cancer; 2007 Jan;94(1):63-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is there still a role for surgery in esophageal carcinoma in 2007?].
  • Regarding curative treatment of oesophageal carcinoma, many therapeutic options could be planned.
  • Surgery is traditionally considered as the most appropriate treatment for locoregional control and long-term survival.
  • Because of the poor prognosis, muldisciplinary approach is necessary, including surgery, radiotherapy and chemotherapy, alone or in association.
  • However, because of the small number of well randomised trials, the question of which treatment is the most appropriate is still under debate.
  • In 2007, following therapeutic strategies could be drawn: surgery is the main treatment, used alone for stages I and IIa, in association with neoadjuvant chemotherapy (CT) or chemoradiation (CRT) for stages IIb.
  • For locally advanced tumours (stage III), adenocarcinomas required neoadjuvant CT or CRT followed by surgery, whereas for squamous cell carcinomas exclusive CRT is the main treatment with following important conditions : (i) response to CRT, (ii) curative salvage surgery in case of non response after 2 cycles or persistent tumour after 4 cycles, (iii) long-term survival may be probably enhanced by adjuvant surgery in experienced centres for selected patients.
  • [MeSH-major] Esophageal Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237006.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 46
  •  go-up   go-down


6. Tomasich FD, Valladares GC, Demarchi VC, Gagliardi D: [Influence of neoadjuvant treatment on morbidity-mortality of esophagectomies]. Rev Assoc Med Bras (1992); 2003 Jul-Sep;49(3):300-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of neoadjuvant treatment on morbidity-mortality of esophagectomies].
  • [Transliterated title] Influência do tratamento neoadjuvante na morbi-mortalidade das esofagectomias.
  • BACKGROUND: To evaluate the influence of neoadjuvant treatment (chemotherapy and/or radiotherapy) on postoperative complications and hospital lethality in patients with esophageal cancer submitted to esophagectomy with two-field lymphadenectomy.
  • METHODS: Retrospective study of 132 patients with esophageal cancer admitted in Department of Surgery in Erasto Gaertner Hospital, from January 1987 to January 1998, divided according to realization of neoadjuvant treatment or not.
  • Variables related to patient (sex, age, general condition, ponderal loss, co-morbidities, tabagism), to tumor (histological type, localization, staging) and to surgical procedure (type and localization of anastomosis, surgical time, hospitalization time) were noted and related to postoperative complications and mortality.
  • The predominant histological type was squamous cell carcinoma in 94.7% of the cases.
  • Six patients (4.54%) were stage I, 44 (33.33%) IIA, 24 (18.18%) IIB, 38 (28.80%) III and 17 (12.90%) IV.
  • Considering the neoadjuvant treatment, 39 patients (29.54%) were submitted to chemotherapy and 22 (16.67%) to radiotherapy.
  • CONCLUSION: Neoadjuvant chemotherapic and radiotherapeutic treatments were related to superior occurrence of postoperative complications, without influence on hospital lethality.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy. Postoperative Complications / mortality
  • [MeSH-minor] Aged. Brazil / epidemiology. Chemotherapy, Adjuvant. Female. Hospital Mortality. Humans. Lymph Node Excision. Male. Morbidity. Multivariate Analysis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666356.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


7. Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, López Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, Pérez X, Germá-Lluch JR: Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol; 2008 Nov 20;26(33):5416-21
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.
  • PURPOSE: To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma.
  • PATIENTS AND METHODS: Untreated patients with pure seminoma of the testis after orchiectomy, with clinical stage IIA or IIB, were considered eligible for this prospective observational study.
  • Chemotherapy consisted of either four cycles of cisplatin and etoposide or three cycles of cisplatin, etoposide, and bleomycin.
  • Eighteen patients had stage IIA disease, and 54 patients had stage IIB disease.
  • After a median follow-up time of 71.5 months, six patients with stage IIB disease experienced relapse, and one of these patients died as a result of seminoma.
  • Three patients experienced non-seminoma-related deaths (two died from a further esophageal carcinoma, and one died from an upper digestive hemorrhage).
  • The estimated 5-year progression-free survival rates for patients with stage IIA or IIB disease were 100% and 87% (95% CI, 77.5% to 97%), respectively.
  • CONCLUSION: Chemotherapy is a highly effective and well-tolerated treatment for patients with stage IIA or IIB seminoma and represents an available alternative that could avoid some of the serious late effects associated with radiotherapy.
  • Further studies focusing on long-term toxicities of different treatment modalities are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Middle Aged. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):2101-2; author reply 2102-3 [19289608.001]
  • (PMID = 18936476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Yano M, Shiozaki H, Tsujinaka T, Inoue M, Doki Y, Fujiwara Y, Monden M: Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Coll Surg; 2000 Dec;191(6):626-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
  • BACKGROUND: The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult.
  • Recently, preoperative chemoradiation therapy has been shown to lead to down-staging of the disease and improve prognosis.
  • But the benefit of this therapy for tumors infiltrating the respiratory tract remains unknown.
  • STUDY DESIGN: Fifty-six patients with thoracic esophageal cancer infiltrating neighboring organs, but with no hematogeneous metastasis, were given preoperative concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation (40 Gy) therapy.
  • Histologic effectiveness (8.3%, 50.0%, and 41.7% versus 25.0%, 70.0%, and 5.0% in grade 3, grade 2, and grade 1, respectively, for patients with respiratory tract invasion versus those without it, p = 0.0189) and histologic stages (8.3%, 8.3%, 8.3%, 8.3%, 25.0%, and 41.7% versus 20.0%, 0%, 15.0%, 25.0%, 40.0%, and 0% in pathologic CR, stage I, stage IIA, stage IIB, stage III, and stage IV, respectively, for patients with respiratory tract invasion versus those without it, p = 0.0496) were significantly better in patients negative for respiratory tract invasion; the percentages of patients with lymph node metastasis did not differ significantly between the two groups.
  • CONCLUSIONS: Because the prognosis of patients with thoracic esophageal cancer infiltrating the respiratory tract is extremely poor, partially because of the low local effectiveness of preoperative concurrent chemotherapy and radiation therapy, caution is needed when deciding on salvage surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Drug Tolerance. Esophageal Neoplasms / pathology. Esophagectomy. Preoperative Care / methods. Radiation Tolerance. Respiratory Tract Neoplasms / secondary. Respiratory Tract Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129811.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Launois B, Raoul JL, Leprise E, Meunier B: [Neoadjuvant treatment in surgery of esophageal cancer]. Bull Acad Natl Med; 2000;184(8):1703-13; discussion 1714
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant treatment in surgery of esophageal cancer].
  • [Transliterated title] Le traitement néoadjuvant dans la chirurgie du cancer de l'oesophage.
  • We conducted a prospective study on neoadjuvant treatment for squamous cell carcinoma of the esophagus, modifying the chemotherapy protocol by adding l-folinic acid and giving bifractionated radiotherapy with a cis-diaminedichloroplatinum (CDDP) injection before each fraction.
  • Thirty-two patients, 30 men, 2 women, mean age 56.2-8.9 years, with resectable squamous celi carcinoma of the esophagus (TNM stage I = 4, IIA = 4, IIB = 13, III = 11) were included.
  • Chemotherapy, CDDP (80 mg/m2: D2), 5-fluorouracil (5-FU; 600 mg/m2, D1-4), and 1-folinic acid (200 mg/m2, DI-4), was given in two sessions with a 3-week interval during which the patients received radiotherapy (45 Gy), two fractions per day (150 cGy/fraction).
  • Patients underwent surgery 4 to 7 weeks after neoadjuvant therapy.
  • This new therapeutic combination is aggressive and associated with a high postoperative mortality but has a remarkable histological effect since complete response was achieved in 56% (95% CI: 39-73%) of the patients and 5-year survival reached 47%, a very high rate in our experience.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / surgery. Esophagectomy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11471389.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Yoon HH, Gibson MK: Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep; 2007 May;9(3):184-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined-modality therapy for esophageal and gastroesophageal junction cancers.
  • The optimal management of locoregional esophageal cancer is controversial.
  • Preoperative concomitant chemoradiotherapy (two courses of cisplatin and 5-fluorouracil plus 50 Gy of radiation) may provide benefit in survival and local control compared with surgery alone and is a reasonable alternative to surgery alone in stages IIB, III, and possibly stage IVa disease.
  • Preoperative chemotherapy without radiation also provides a survival benefit compared with surgery alone, but data are insufficient to conclude it is superior to preoperative chemoradiotherapy.
  • Control of distant disease remains a problem with preoperative chemotherapy and preoperative chemoradiotherapy.
  • [MeSH-major] Esophageal Neoplasms / therapy. Esophagogastric Junction / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Fluorouracil / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Metastasis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2347-54 [15160337.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):120-7 [12909224.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001799 [16235286.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):391-3 [7959579.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1349-55 [16130133.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8 [2456424.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001556 [16855972.001]
  • [Cites] J Surg Oncol. 1994 Jul;56(3):191-7 [7518020.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34 [12738305.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):868-76 [10673530.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1446-50 [1365692.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2165-74 [11391598.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):794-802 [16187480.001]
  • (PMID = 17430689.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 37
  •  go-up   go-down


11. Kube R, Reimer A, Laube T, Gastinger I: [Surgical treatment of esophageal cancer]. Khirurgiia (Mosk); 2009;(9):50-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of esophageal cancer].
  • Prospective study, included 117 patients with esophageal cancer, all received resection of the esophagus through laparatomy and and right-side thoracotomy without neoadjuvant chemotherapy.
  • 70,0% of patients demonstrated stage higher then IIb UICC.
  • Surgical treatment alone does not provide satisfactory results for the patients with cancer of esophagus.
  • Further therapy individualization and combination of surgery with modern neoadjuvant chemotherapy can provide better prognosis for these patients.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Laparotomy / methods. Thoracotomy / methods
  • [MeSH-minor] Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Prospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770824.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


12. Javle MM, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR: Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus; 2006;19(2):78-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of locoregional stage esophageal cancer: a single center experience.
  • Therapeutic options for locoregional esophageal cancer (EC) include primary surgery, neoadjuvant or definitive chemoradiation and systemic chemotherapy.
  • The role of surgery in these multimodal strategies has recently been debated and definitive chemoradiation is being offered as an alternative to surgery at many centers.
  • We examined our results with multimodal therapy and surgery in this patient population.
  • We conducted a retrospective analysis of 172 patients with locoregional (AJCC stages I-III) EC treated at RPCI between February 14, 1990 and September 20, 2002.
  • There were 100 regional (stages IIB-III), 69 local (stages I-IIA) and three in situ cases.
  • Initial therapy was either combined modality (n = 122) or single modality (surgery) (n = 50).
  • Median survival for all patients was 25.3 months and was better for local stage with surgery alone (75 months) than with neoadjuvant (35.7 months) or definitive chemoradiation (19.1 months, P < 0.001).
  • Survival for patients with regional disease treated with surgery alone, neoadjuvant or definitive chemoradiation was 21.5, 24.4 and 11.8 months, respectively (P = not significant).
  • On multivariate analysis, carefully selected patients treated with surgery alone had better outcomes compared with those treated with definitive chemoradiation (P < 0.001).
  • Patients with locoregional esophageal cancer who are eligible for surgical resection either alone or as a part of multimodal therapy may have better outcomes than those treated with non-surgical approaches.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643174.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC: Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg; 2001 Jun;71(6):1803-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ivor Lewis esophagogastrectomy for esophageal cancer.
  • BACKGROUND: To examine the efficacy of the Ivor Lewis esophagogastrectomy for esophageal carcinoma prior to the widespread use of preoperative chemotherapy and irradiation, we reviewed our experience.
  • METHODS: We reexamined the cases of 220 consecutive patients who underwent an Ivor Lewis esophagogastrectomy for esophageal cancer from January 1992 through December 1995.
  • The results of pathological study showed adenocarcinoma in 188 patients (85.5%), squamous cell carcinoma in 31 (14.1%), and leiomyosarcoma in 1 patient (0.5%).
  • Postsurgical staging was as follows: stage 0 in 10 patients, stage I in 19, stage IIa in 38, stage IIb in 28, stage III in 111, and stage IV in 14.
  • The overall 5-year survival rate was 25.2%; it was 80% for patients in stage 0, 94.4% for those in stage I, 36.0% for those in stage IIa, 14.3% for patients in stage IIb, 10% for those in stage III and 0% for patients in stage IV.
  • CONCLUSIONS: Ivor Lewis esophagogastrectomy for esophageal cancer is a safe operation.
  • Long-term survival is stage dependent.
  • The low survival associated with advanced cancers should stimulate the search for effective neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrectomy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426751.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hilbig A, Stieler J, Pelzer U, Okenga J, Hintze R, Roll L, Gövercin M, Arning M, Riess H, Oettle H: Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC).
  • : 4238 Background: Our previous phase I study has shown that combination chemotherapy with gemcitabine, 5-FU/FA, and cisplatin (GFFC) is feasible and has encouraging activity in IEC.
  • Therefore, we initiated a multicenter phase II study of outpatient GFFC treatment for IEC.
  • METHODS: A two-stage design was used, 11 or more of the first 25 evaluable patients (pts) were required to achieve at least SD to complete enrolment to a total of 66 pts.
  • Treatment consists of cisplatin 30 mg/m<sup>2</sup> (90 min), gemcitabine 1000 mg/m<sup>2</sup> (30 min), FA 200 mg/m<sup>2</sup> (30 min), and 5-FU 750 mg/m<sup>2</sup> (24h) on days 1 + 8 q3w.
  • Two pts had stage IIB, 17 stage III, 9 stage IVA and 13 stage IVB.
  • We therefore opened the second stage of our study, and recruitment is ongoing.
  • Updated results will be available at the time of the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Horgan AM, Darling G, Wong R, Visbal A, Guindi M, Jonker D, Liu G, Hornby J, Xu W, Knox JJ: Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial.
  • : e15550 Background: Locally advanced esophageal cancer (LAEC) has a 5-year survival of < 30 %.
  • Most patients (pts) fail after curative intent tri-modality treatment with distant metastatic disease.
  • This phase II trial aims to determine if adjuvant targeted therapy, after neoadjuvant CRT plus surgery for resectable LAEC, may impact on systemic disease without significant toxicity.
  • METHODS: Pts with LAEC of the thoracic esophagus or gastroesophageal junction, ECOG PS 0,1 and surgical candidates treated with: preoperative Irinotecan (65mg/m<sup>2</sup> initially, ammended to 50mg/m<sup>2</sup>) + Cisplatin (30mg/m<sup>2</sup>) on weeks 1,2,4,5,7,8 + concurrent conformal radiotherapy (50Gy/25 fractions) on weeks 4-8.
  • Median age 64 yr (43-71), male: 22, adenocarcinoma: squamous 22:6; 10 pts stage IIA, 5 IIB and 13 III.
  • 28 pts completed CRT - 18 pts (64%) received ≥80% of planned chemotherapy dose, 23 pts (82%) received full radiation dose.
  • 2 deaths on chemotherapy (1 bacterial meningitis, 1 FN) leading to irinotecan dose- reduction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962341.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA: Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys; 2003 Jun 1;56(2):328-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
  • PURPOSE: To assess the long-term survival results after cisplatin, protracted infusion 5-fluorouracil, and concurrent radiotherapy (RT) followed by surgical resection of esophageal cancer.
  • METHODS AND MATERIALS: Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy.
  • The patients had tumor confined to the esophagus and regional nodes, including celiac nodes for middle and distal lesions.
  • In trial A (1989-1994), 50 patients were treated with 44 Gy RT (2 Gy/d) along with concurrent 5-fluorouracil 300 mg/m(2)/d given by protracted venous infusion on Days 1-30 and cisplatin 26 mg/m(2) on Days 1-5 and 26-30.
  • In trial B (1995-1997, 42 patients), the chemotherapy dosages during RT were reduced to 5-fluorouracil 225 mg/m(2)/d protracted venous infusion and cisplatin 20 mg/m(2)/d on Days 1-5 and 16-30; three cycles of paclitaxel 135 mg/m(2)and cisplatin 75 mg/m(2) were given postoperatively.
  • Surgery generally occurred 4-6 weeks after completion of the planned preoperative therapy.
  • RESULTS: Of the 92 patients, 86 (93%) underwent surgery (1 refused, 2 died preoperatively, and 3 developed evidence of metastatic disease).
  • Eight patients with pathologic Stage I tumor at the time of surgery had survival similar to those with a complete response to preoperative therapy.
  • The median survival for patients with pathologic Stage IIA, IIB, III, and IV disease at the time of surgery was 22, 13.5, 18, and 4.9 months, respectively.
  • No differences were noted in survival or response rate between those with adenocarcinoma or squamous cell carcinoma.
  • CONCLUSION: The promising 5-year survival results and low rate of late cancer-related deaths suggest that these regimens of intensive neoadjuvant therapy may improve the overall cure rate.
  • The pathologic stage after neoadjuvant therapy is an important predictor of survival and may be useful in selecting patients for novel adjuvant therapies.
  • Isolated local failure is uncommon, indicating that efforts to improve the therapeutic outcome should focus on optimizing systemic therapy rather than intensifying the RT.
  • Additional randomized data are needed to assess the benefits of this therapeutic approach fully.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738305.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Okamura H, Fujiwara H, Suchi K, Okamura S, Umehara S, Konishi H, Todo M, Kubota T, Ichikawa D, Kikuchi S, Okamoto K, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Otsuji E: [Surgically resected local recurrence after endoscopic submucosal dissection of esophageal cancer--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2448-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgically resected local recurrence after endoscopic submucosal dissection of esophageal cancer--a case report].
  • We report a case of surgically resected esophageal cancer which was locally recurred after endoscopic submucosal dissection.
  • A 66-year-old man was admitted to our hospital because of further examination and a treatment of superficial esophageal cancer.
  • A type 0-IIb+IIa cancer occupying the whole circumference of the lumen of the middle to lower esophagus was revealed.
  • However, macroscopic residual cancer didn't seem to exist.
  • Pathological diagnosis was squamous cell carcinoma, moderately differentiated, the depth of tumor invasion was T1a-LPM.
  • The presence of the residual cancer of the horizontal cut margin could not be judged because en bloc resection could not be achieved.
  • After that, endoscopic balloon dilatation of the esophageal stenosis was performed repeatedly for about one year.
  • Then, he was diagnosed as the local recurrence of the squamous cell carcinoma of the esophagus.
  • The final stage of the lesion was judged T3N1M0 (Stage III, UICC) by the histological examination from the resected specimen.
  • After the operation, he is receiving adjuvant chemotherapy and alive without recurrence.
  • When endoscopic resection of the esophageal cancer is performed to the lesion, which relatively indicated to endoscopic resection or outside the guideline criteria for endoscopic resection, it is important that we choose the appropriate treatment protocol obtaining an informed consent from the patient sufficiently.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Esophagoscopy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Recurrence, Local / surgery. Reoperation

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH: Lymphadenectomy extent is closely related to long-term survival in esophageal cancer. Eur J Cardiothorac Surg; 2007 Feb;31(2):154-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy extent is closely related to long-term survival in esophageal cancer.
  • OBJECTIVE: The optimal extent of lymphadenectomy during esophagectomy for esophageal cancer remains debatable.
  • The aim of this study was to identify the effect of the extent of lymphadenectomy on survival and recurrence after esophagectomy in esophageal cancer.
  • MATERIALS AND METHODS: Two hundred thirty-three patients who were operated on between January 1995 and December 2003 due to esophageal cancer were included.
  • The study subjects were stage I, II, and III esophageal squamous cell carcinoma patients who had undergone curative resection without neoadjuvant chemotherapy or chemoradiation therapy.
  • RESULTS: The pathologic stages were stage I in 57 (24.5%), IIA in 69 (29.6%), IIB in 27 (11.6%), and III in 80 (34.3%).
  • CONCLUSIONS: A wider extent of lymphadenectomy in esophageal cancer was associated with better long-term survival than limited lymphadenectomy, especially in N0 patients.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145185.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Stilidi I, Davydov M, Bokhyan V, Suleymanov E: Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. Eur J Cardiothorac Surg; 2003 Mar;23(3):415-20
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer.
  • OBJECTIVE: To examine the efficacy of the Ivor Lewis esophagectomy with extended 2-field lymph node dissection for thoracic esophageal carcinoma we reviewed our experience.
  • METHODS: We analyzed the cases of 147 consecutive patients who underwent subtotal esophagectomy with extended 2-field lymph node dissection through Ivor Lewis approach for esophageal cancer from January 1996 through December 2000.
  • Eighty-six patients were operated on for cancer of the midthoracic esophagus, 48 for cancer of the lower thoracic esophagus, and 13 for cancer of the aortal segment of the esophagus.
  • No patient had received chemotherapy or radiotherapy before operation.
  • Postsurgical pathological studies revealed squamous cell carcinoma in 139 patients (94.6%), adenocarcinoma in five (3.4%), and adenosquamous carcinoma in three (2%).
  • Postsurgical staging was as follows: stage I in three patients (2%), stage IIa in 20 (13.6%), stage IIb in 29 (19.7%), stage III in 54 (36.8%), and stage IV in 41 (27.9%).
  • The 5-year survival rate for patients in stage IIa was 59%; for those in stage IIb, 39.5%; for patients in stage III, 26.7%; and 0% for patients in stage IV.
  • CONCLUSIONS: Subtotal esophagectomy with extended 2-field lymph node dissection through Ivor Lewis approach for esophageal cancer is a safe operation.
  • Long-term survival is stage dependent.
  • Effective multimodality treatment may be helpful for patients with advanced disease.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12614816.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet JC, Gerard JP: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer; 2000 Sep 1;89(5):946-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus.
  • BACKGROUND: Surgery remains the treatment of choice for patients with esophageal squamous cell carcinoma (SCC), but survival rates have not improved over the past decades.
  • The objective of this study was to evaluate the effect of multimodal therapy on resectability, on the overall and on disease free survival (DFS) rates, and on the laryngeal resection rate.
  • METHODS: Fifty-five patients (49 men and 6 women) with a mean age of 58 +/- 8 years underwent combined modality treatment for esophageal SCC.
  • The tumor location was in the upper one-third of the esophagus in 19 patients, the middle one-third in 22 patients, the lower one-third in 9 patients, and the upper and lower one-thirds in 5 patients.
  • The intent of combined therapy was curative in 87.3% of patients and palliative in 12.7% of patients.
  • Neoadjuvant treatment consisted of two courses of 5-fluorouracil and cisplatin on Days 1-5 and Days 21-25.
  • RESULTS: Full neoadjuvant treatment was possible in 67.3% of patients and was uneventful in 56.
  • The tumor stages according to the American Joint Committee on Cancer staging system were pT0N0 in 12 patients, Stage 0 in 8 patients, Stage IIa in 6 patients, Stage IIb in 6 patients, Stage III in 8 patients, and Stage IV in 13 patients.
  • CONCLUSIONS: Neoadjuvant treatment is tolerated well by most patients.
  • Combination therapy increases the resectability rate and facilitates laryngeal preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Larynx / surgery. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Rate. Treatment Outcome


21. Constantinoiu S, Hanna A, Bîrlă R, Anghel R, Tavlas E, Mocanu A, Hoară P: [Principles of treatment in locally advanced esophageal squamous cancer]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):7-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Principles of treatment in locally advanced esophageal squamous cancer].
  • The diagnosis established in the symptomatic phase of this disease, most often occurs at advanced stage neoplasia.
  • The purpose of this article is to establish the place and method of surgical and radio-chemo therapy in advanced loco-regional squamous esophageal neoplasm (stage IIB-III).
  • Surgical treatment establishes the best results over long periods of time, however, this is done keeping in mind acceptable morbidity and mortality conditions.
  • Multimodal treatment is encompassed in general efforts to achieve optimal results along with increasing the quantity and quality of life.
  • Neoadjuvant radiochemotherapy (CRT) increases practitioners' possibility of resecting tumors, decreasing their size, and establishing proper means of local (radiotherapy) and systemic (chemotherapy) control.
  • Great efforts are made in finding markers which lead to correct diagnosis and treatment options that will further permit nonresponsive radio and chemo therapy treated patients from experiencing unwanted toxicity.
  • The role of adjuvant therapy is that of decreasing recurrence in patients with residual mediastinal disease after palliative surgical resection.
  • Palliative treatment consists of improving dysphagia, and the quality of life using surgical, endoscopic, photodynamic, laser, radio and chemotherapy as alternatives.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Esophagectomy. Humans. Neoadjuvant Therapy / methods. Neoplasm Staging. Quality of Life. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405674.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 38
  •  go-up   go-down


22. Kenjo M, Uno T, Murakami Y, Nagata Y, Oguchi M, Saito S, Numasaki H, Teshima T, Mitsumori M: Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001.
  • PURPOSE: To describe patient characteristics and the process of radiotherapy (RT) for patients with esophageal cancer treated between 1999 and 2001 in Japan.
  • Detailed information was accumulated on 621 patients with thoracic esophageal cancer who received RT.
  • Ninety-nine percent had squamous cell carcinoma histology.
  • Fifty-five percent had the main lesion in the middle thoracic esophagus.
  • Fourteen percent had clinical Stage 0-I disease, 32% had Stage IIA-IIB, 43% had Stage III, and 10% had Stage IV disease.
  • Chemotherapy was given to 63% of patients; 39% received definitive chemoradiotherapy (CRT) without surgery and 24% pre- or postoperative CRT.
  • Median total dose of external RT was 60 Gy for definitive CRT patients, 60 Gy for RT alone, and 40 Gy for preoperative CRT.
  • CONCLUSIONS: This PCS describes general aspects of RT for esophageal cancer in Japan.
  • Squamous cell carcinoma accounted for the majority of patients.
  • The standard total external RT dose for esophageal cancer was higher in Japan than in the United States.
  • Chemoradiotherapy had become common for esophageal cancer treatment, but patients aged > or =75 years were more likely to be treated by RT only.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / radiotherapy. Health Care Surveys
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy / methods. Combined Modality Therapy / utilization. Female. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Radiotherapy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J, Carolina Conformal Therapy Consortium: Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol; 2004 Nov 1;22(21):4329-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
  • PURPOSE: To prospectively determine the maximum-tolerated dose of accelerated hyperfractionated conformal radiotherapy (RT; 1.6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N).
  • METHODS: Induction chemotherapy, C/T or C/N, was followed by escalating doses of conformally-planned RT (73.6 to 86.4 Gy in 6.4-Gy increments).
  • Concurrent boost methods delivered 1.6 and 1.25 Gy bid to the gross and clinical target volumes, respectively.
  • RESULTS: Between November 1997 and February 2002, 44 patients were enrolled (median age, 59 years; 59% male; stage III, 98%; median tumor size, 4 cm).
  • Thirty-nine patients completed induction chemotherapy: 19 had a partial response, seven progressed, 15 had no response, and three were not assessable.
  • Chemotherapy-associated toxicities were similar in the two chemotherapy groups.
  • The incidence of grade > or = 3 RT-induced toxicity was 1/13, 2/14, and 4/12 at 73.6, 80, and 86.4 Gy, respectively, thus defining the maximum tolerated dose at approximately 80 Gy.
  • Toxicities were in both lung and esophagus and were similar in the two chemotherapy arms.
  • CONCLUSION: High-dose conformal twice-daily radiation therapy to approximately 80 Gy appears tolerable in well-selected patients with unresectable lung cancer following either C/T or C/N.
  • Dose-limiting toxicities are mainly pulmonary and esophageal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Dose Fractionation. Esophagus / pathology. Esophagus / radiation effects. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15514374.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  •  go-up   go-down


24. Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol; 2007 Jun;8(6):545-53
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.
  • Traditionally, surgery is considered the best treatment for oesophageal cancer in terms of locoregional control and long-term survival.
  • However, survival 5 years after surgery alone is about 25%, and, therefore, a multidisciplinary approach that includes surgery, radiotherapy, and chemotherapy, alone or in combination, could prove necessary.
  • The role of each of these treatments in the management of oesophageal cancer is under intensive research to define optimum therapeutic strategies.
  • In this report we provide an update on treatment strategies for resectable oesophageal cancers on the basis of recent published work.
  • Results of the latest randomised trials allow us to propose the following guidelines: surgery is the standard treatment, to be used alone for stages I and IIa, or possibly with neoadjuvant chemotherapy or chemoradiotherapy for stage IIb disease.
  • For locally advanced cancers (stage III), neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate for adenocarcinomas.
  • Chemoradiotherapy alone should only be considered in patients with squamous-cell carcinomas who show a morphological response to chemoradiotherapy, and produces a similar overall survival to chemoradiotherapy followed by surgery, but with less post-treatment morbidity.
  • Although the addition of surgery to chemotherapy or chemoradiotherapy could result in improved local control and survival, surgery should be done in experienced hospitals where operative mortality and morbidity are low.
  • Moreover, surgery should be kept in mind as salvage treatment in patients with no morphological response or persistent tumour after definitive chemoradiotherapy.
  • [MeSH-major] Esophageal Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy / methods. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540306.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


25. McClave SA, Jones WF, Evans WB: Do physician attitudes and practices limit use of EUS in the staging and the treatment of esophageal carcinoma? Gastrointest Endosc; 2005 Jun;61(7):840-8
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do physician attitudes and practices limit use of EUS in the staging and the treatment of esophageal carcinoma?
  • BACKGROUND: Although EUS provides superior local staging of esophageal carcinoma when compared with other tests, EUS seems to be underused by physicians.
  • We designed this prospective study to determine whether EUS is ordered in the evaluation of esophageal cancer and whether staging information obtained would change management.
  • METHODS: A total of 114 physicians were mailed a questionnaire that surveyed which tests are used in evaluating patients with esophageal cancer, the order in which they are requested, and their estimated cost.
  • Physicians were asked to estimate prognosis and to indicate which therapy would be used for each specific TNM cancer stage.
  • Only 47.3% of physicians would use EUS in the patient workup for esophageal cancer.
  • A significantly greater number of internists (78.9%, p = 0.055) would not order EUS, and 31.6% of internists would not use any staging data before referral to another physician for definitive management.
  • Physicians were accurate in their assessment of the prognosis for each cancer stage and the cost of each test.
  • However, significantly more surgeons than nonsurgeons would use surgery for stage IIB (100.0% vs. 71.3%, p = 0.019), with a trend toward greater use by surgeons for stage III (64.3% vs. 34.1%, p = 0.11).
  • Except for significantly greater use of chemotherapy by surgeons and oncologists for stage IIA than internists and gastroenterologists (36.6% vs. 3.1%, p = 0.0006), there were no differences between subspecialties with use of chemotherapy for all other stages or use of radiation therapy for any stage.
  • CONCLUSIONS: Clinicians have an adequate understanding of patient survival based on cancer stage and a reasonable appreciation of cost for diagnostic tests regarding esophageal carcinoma.
  • Specific data on cancer staging does impact treatment choices and management decisions.
  • EUS is grossly underused by clinicians for staging esophageal cancer.
  • The ultimate modality of treatment may be more related to the type of physician that the patient is referred to, instead of the specific cancer stage.
  • [MeSH-major] Attitude of Health Personnel. Carcinoma / diagnostic imaging. Endosonography / utilization. Esophageal Neoplasms / diagnostic imaging. Physicians. Practice Patterns, Physicians'
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Barium Sulfate. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Contrast Media. Esophagoscopy. Gastroenterology. General Surgery. Humans. Internal Medicine. Medical Oncology. Neoplasm Staging. Patient Care Planning. Prognosis. Prospective Studies. Radiopharmaceuticals / therapeutic use. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933685.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


26. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • BACKGROUND: Several techniques for esophageal resection have been reported.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • METHODS: Three hundred forty-two patients had surgery for esophageal carcinoma between 1989 and 2000 at our institution.
  • Kaplan-Meier curves and univariate and multivariate analyses were performed by postsurgical pathologic stage.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Overall survival at 3 years was 44%; median survival was 25 months, and 3-year survival by posttreatment pathologic stage was: stage 0 (complete response) (n = 60), 56%; stage I (n = 32), 65%; stage IIA (n = 67), 41%; stage IIB (n = 30), 46%; and stage III (n = 49), 17%.
  • Five patients with tumor in situ, 6 patients with stage IV disease, and 1 patient who could not be staged (12 pts) were excluded from survival and multivariate calculations.
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • Preoperatively 30 patients (eight in stage IIB, 18 in stage III, and four in stage IV) received radiochemotherapy.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


28. Lü JM, Liang J, Wang JW, He J, Xiao ZF, Zhang HX, Chen DF, Feng QF, Wang LH: [Clinical analysis of 126 patients with primary small cell carcinoma of the esophagus]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):121-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 126 patients with primary small cell carcinoma of the esophagus].
  • OBJECTIVE: To investigate the prognostic factors and the principles of treatment of primary esophageal small cell carcinoma (SCEC) retrospectively.
  • 85 patients were in limited disease stage (LD) and 41 patients as extensive disease stage (ED) according to the Veterans Administration Lung Study Group staging system.
  • Among the 84 patients treated with esophagectomy, 8 cases were in stage I, 16 in stage IIa, 10 in stage IIb, 40 in stage III, 4 in stage IVa and 6 in stage IVb, according to the TNM system (6(th) edition, AJCC).
  • The 1-, 3-, and 5-year overall survival rates (OS) were 52.2%, 15.9%, and 12.2%, respectively, with a median survival time (MST) of 12.5 months.
  • The MST of the patients treated with chemotherapy was 14.5 months, significantly longer than the 5.2 months of the patients without (P = 0.0001).
  • Multivariate analysis showed that stage (HR 1.91, 95% CI 1.26 approximately 2.91, P = 0.002), length of the primary lesion (HR 1.75, 95% CI 1.17 approximately 2.63, P = 0.007), and chemotherapy (HR 0.42, 95% CI 0.28 approximately 0.65, P = 0.000) were independent prognostic factors.
  • CONCLUSION: Esophageal small cell carcinoma is a systemic disease.
  • The tumor stage (LD or ED), length of the primary lesion and chemotherapy are independent prognostic factors.
  • Therefore, a systemic therapy based on chemotherapy should be recommended.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538888.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Delcambre C, Jacob JH, Pottier D, Gignoux M, Ollivier JM, Vie B, Roussel A, Segol P: Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules. Radiother Oncol; 2001 May;59(2):195-201
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules.
  • BACKGROUND AND PURPOSE: A retrospective study comparing chemotherapy and radiation, esophagectomy alone versus preoperative radiochemotherapy and surgery in localized squamous-cell esophageal carcinoma.
  • MATERIALS AND METHODS: Between 1989 and 1995, 139 patients (40 stage I, 77 stage IIA and 22 stage IIB according to the UICC 78 TNM classification) were treated in two different institutions.
  • They were divided into three groups according to the treatment proposed: E group (treatment by esophagectomy; n = 30), RCT+E group (treatment by preoperative radiochemotherapy and esophagectomy; n = 46), RCT group (treatment by radiochemotherapy; n = 63).
  • Factors like age, tumor localization and stage were similar in all groups.
  • CONCLUSIONS: Treatments by esophagectomy or radiochemotherapy were not significantly different.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy / mortality. Fluorouracil / administration & dosage. Humans. Middle Aged. Mitomycin / administration & dosage. Palliative Care. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11325449.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Benhidjeb T, Moesta KT, Schlag PM: [Staging and neoadjuvant therapy of squamous cell carcinoma of esophagus]. Ther Umsch; 2001 Mar;58(3):165-73
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Staging and neoadjuvant therapy of squamous cell carcinoma of esophagus].
  • [Transliterated title] Staging und neoadjuvante Therapie des Plattenepithelkarzinoms des Osophagus.
  • Once the diagnosis of esophageal cancer is established, the decision on treatment will depend on the stage of the disease.
  • Since improvement of prognosis can only be expected in patients with complete removal of their tumor, preoperative staging plays a pivotal role in the decision-making process.
  • Endosonography represents currently the most accurate imaging technique for detecting the correct T stage over the correct N stage.
  • A higher accuracy rate may be achieved by combining endosonography with other staging modalities such as computed tomography.
  • Computed tomography (neck, chest and abdomen) is currently the best method to detect metastases in the liver and in celiac nodes.
  • Staging laparoscopy when combined with laparoscopic ultrasonography shows a higher sensitivity than ultrasonography and computed tomography in the diagnosis of smaller metastases and peritoneal seedings.
  • En bloc esophagectomy together with the regional lymph nodes remains the treatment of choice in medically fit patients with localized esophageal carcinoma (Stage I-IIB, T1-T2/N0-N1/M0).
  • Due to early involvement of mediastinal structures, curative resection is unlikely to be achieved in patients with locally advanced esophageal carcinoma (Stage III, T3-T4/N0-N1/M0).
  • At present, neoadjuvant therapy is still experimental and there is no consensus for an optimal treatment regimen.
  • Future research must focus on more effective and less toxic neoadjuvant modalities (e.g. new chemotherapy agents, hyperthermia).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Seeding. Neoplasm Staging. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305155.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 30
  •  go-up   go-down


31. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • In 5 cases the tumors were located in the mid-esophagus, 3 cases in the lower third of the esophagus and 1 case in the upper third.
  • The average length of esophageal involvement was 5 cm.
  • They underwent radical resection, regional lymph node clearance and esophageal-stomach anastomosis in thorax or at neck.
  • Two patients had a stage IIa disease, five had a stage IIb disease, and the other two had a stage III disease of International Union Contrele Cancer (UICC).
  • All of them were histologically and immunohistochemically confirmed SCC of esophagus.
  • Three of the nine resected specimens showed foci of squamous cell carcinoma in situ.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down






Advertisement